Obesity — Insulin and Biogenic Amines in Cardiovascular Disease
Citation(s)
Cassano PA, Rosner B, Vokonas PS, Weiss ST Obesity and body fat distribution in relation to the incidence of non-insulin-dependent diabetes mellitus. A prospective cohort study of men in the normative aging study. Am J Epidemiol. 1992 Dec 15;136(12):1474-86.
Cassano PA, Segal MR, Vokonas PS, Weiss ST Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol. 1990 Oct;1(1):33-48.
Daly PA, Landsberg L Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system. Diabetes Care. 1991 Mar;14(3):240-8. Review.
Daly PA, Landsberg L Pathogenesis of hypertension in NIDDM: lessons from obesity. J Hum Hypertens. 1991 Aug;5(4):277-85. Review.
Hu H, Sparrow D, Weiss S Association of serum albumin with blood pressure in the normative aging study. Am J Epidemiol. 1992 Dec 15;136(12):1465-73.
Krieger DR, Landsberg L Mechanisms in obesity-related hypertension: role of insulin and catecholamines. Am J Hypertens. 1988 Jan;1(1):84-90. Review.
Landsberg L, Young JB Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S29-34. Review.
Landsberg L Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986 Dec;61(236):1081-90. Review.
Landsberg L Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension. 1992 Jan;19(1 Suppl):I61-6. Review.
Landsberg L Insulin and hypertension: lessons from obesity. N Engl J Med. 1987 Aug 6;317(6):378-9.
Landsberg L Insulin resistance, energy balance and sympathetic nervous system activity. Clin Exp Hypertens A. 1990;12(5):817-30. Review.
Landsberg L Obesity and hypertension: experimental data. J Hypertens Suppl. 1992 Dec;10(7):S195-201.
Landsberg L Obesity, metabolism, and hypertension. Yale J Biol Med. 1989 Sep-Oct;62(5):511-9. Review.
Landsberg L Obesity-related hypertension and the insulin resistance syndrome. Trans Am Clin Climatol Assoc. 1995;106:69-75; discussion 75-6. Review.
Landsberg L Pathophysiology of obesity-related hypertension: role of insulin and the sympathetic nervous system. J Cardiovasc Pharmacol. 1994;23 Suppl 1:S1-8. Review.
Landsberg L The sympathoadrenal system, obesity and hypertension: an overview. J Neurosci Methods. 1990 Sep;34(1-3):179-86. Review.
Lipsitz LA, Jonsson PV, Marks BL, Parker JA, Royal HD, Wei JY Reduced supine cardiac volumes and diastolic filling rates in elderly patients with chronic medical conditions. Implications for postural blood pressure homeostasis. J Am Geriatr Soc. 1990 Feb;38(2):103-7.
Young JB, Macdonald IA Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord. 1992 Dec;16(12):959-67. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
